Dr. Michael May

CEO, Centre for Commercialization of Regenerative Medicine

Dr. Michael May

Dr. May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship.

Michael May is currently President and Chief Executive Officer of the Centre for Commercialization of Regenerative Medicine (CCRM), a Canadian, federally incorporated, not-for-profit organization dedicated to supporting the development of foundational technologies that accelerate the commercialization of stem cell-and biomaterials-based technologies. Prior to CCRM, Michael was the President, and co-founder, of Rimon Therapeutics Ltd., a Toronto-based regenerative medicine company developing novel medical polymers that possess drug-like activity. Michael sits on a number of Boards and advisory committees including:  MaRS Innovation; 20/20 Vision a centre of excellence for biomaterials in ophthalmology; the Industry Committee of the International Society for Stem Cell Research; the Rick Hansen Institute Commercialization Program Advisory Committee; the Biozone and Bioproducts + Enzymes from Environmental Metagenomes Commercialization Committee; and, the Department of Chemical Engineering and Applied Chemistry at the University of Toronto.